Sigma-Aldrich

Patrick M. Sullivan has been named vice president of R&D for the Research Biotech business unit of Sigma-Aldrich. In this role, he will help expand the company’s leadership position through the development of new and innovative products for life science researchers. Mr. Sullivan has been a member of the company’s scientific advisory board, since 2005 and provided a large pharmaceutical perspective on new strategic plans and product offerings in the company’s Research Biotech business unit. He will report to David A. Smoller, Ph.D., president of Research Biotech.

Mr. Sullivan has more than 19 years of experience using and developing genomic-based solutions for the pharma and biopharma industries. He worked at  Monsanto/Searle/Pharmacia for 12 years, where he provided molecular biology support for Inflammation and angiogenesis new target/biomarker discovery projects. In 2000, he joined Incyte Genomics as vice president of global operations, responsible for managing all genomic products and services. Most recently, Mr. Sullivan led efforts to identify new therapeutic opportunities in osteoarthritis and cardiovascular diseases at Pfizer.

“We are pleased to have such an strong and experienced leader join our organization,” Dr. Smoller. “Patrick’s combination of technical expertise, strong ability to analyze complex business operations and implement strategies to improve performance will be an immediate asset to our Research Biotech business unit’s mission of bringing innovative technologies and solutions to life science researchers. We look forward to having him join us in making these valuable contributions to our life science community.”